PF-Atlas › Clinical Trials › NCT00449904

Open-Label Phase III Long-Term Safety Trial of Liprotamase

Liprotamase · Phase 3

Registry ID
NCT00449904
Phase
Phase 3
Status
Completed
Drug / intervention
Liprotamase
Sponsor
Anthera Pharmaceuticals
Start
2007-06
Enrollment
214
Locations
39

About this trial

This is an open-label, single-arm clinical study investigating the long-term safety of ALTU-135 treatment in patients with cystic fibrosis (CF)-related exocrine pancreatic insufficiency (PI).

View NCT00449904 on ClinicalTrials.gov →

Explore related

All Liprotamase trialsAll IPF trials

Related trials

Liprotamase — NCT00095732Liprotamase — NCT02823964
Medical disclaimer. This page summarizes public trial data for NCT00449904 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.